Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision proton beams aim to shrink brain tumors with fewer side effects

NCT ID NCT01358058

Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a precise type of radiation called proton therapy for people with slow-growing brain tumors (low-grade gliomas). The goal is to see if it can control tumor growth as well as standard radiation while causing fewer side effects by sparing healthy brain tissue. About 63 participants will receive proton radiation and be followed for tumor control and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

63 people

The number who actually took part.

Start date

May 2011

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed low-grade gliomas OR Grade III anaplastic glioma with either or both IDH1 mutation or 1p/19q codeletion * Subject must be indicated for radiation therapy * Life expectancy greater than 5 years * Willing to participate in rigorous neurocognitive evaluations at baseline and serially following treatment * Able to speak and comprehend English * Recovered from adverse events due to agents administered more than 4 weeks before entering study * Able to undergo MRI scans Exclusion Criteria: * Prior cranial radiation therapy * Chemotherapy within 4 weeks prior to entering study * Pregnant or breastfeeding * Known brain metastases * Baseline neurocognitive or emotional disorders * Uncontrolled intercurrent illness * History of a different malignancy unless disease-free for at least 5 years * HIV positive on antiretroviral therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low-grade glioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 3 brain cancer glioma grade III glioma low grade glioma oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Low-grade glioma Who grade 3 glioma with 1p/19q codeletion Who grade 3 glioma with IDH1 mutation

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.